Subhashis Banerjee Sells 8,222 Shares of Artiva Biotherapeutics (NASDAQ:ARTV) Stock

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) insider Subhashis Banerjee sold 8,222 shares of the firm’s stock in a transaction dated Thursday, August 27th. The stock was sold at an average price of $12.01, for a total transaction of $98,746.22. Following the completion of the transaction, the insider directly owned 142,047 shares in the company, valued at $1,705,984.47. This represents a 5.47% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Subhashis Banerjee also recently made the following trade(s):

• On Tuesday, August 18th, Subhashis Banerjee sold 429 shares of Artiva Biotherapeutics stock. The shares were sold at an average price of $12.00, for a total transaction of $5,148.00.

Artiva Biotherapeutics Price Performance

Artiva Biotherapeutics stock opened at $11.28 on Wednesday. The stock has a market cap of $551.48 million, a price-to-earnings ratio of -3.42 and a beta of 2.16. The firm has a 50-day moving average of $10.45 and a two-hundred day moving average of $8.63. Artiva Biotherapeutics, Inc. has a 1 year low of $2.22 and a 1 year high of $14.53.

Artiva Biotherapeutics (NASDAQ:ARTV) last issued its earnings results on Thursday, August 6th. The company reported ($0.63) EPS for the quarter, hitting analysts’ consensus estimates of ($0.63). Research analysts expect that Artiva Biotherapeutics, Inc. will post -2.62 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the company. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Artiva Biotherapeutics in a research report on Tuesday, May 26th. Weiss Ratings reissued a “sell (d-)” rating on shares of Artiva Biotherapeutics in a research report on Tuesday, July 21st. Needham & Company LLC restated a “buy” rating and set a $41.00 price target on shares of Artiva Biotherapeutics in a research note on Monday, June 8th. Wall Street Zen upgraded Artiva Biotherapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 8th. Finally, Wedbush upped their price objective on shares of Artiva Biotherapeutics from $23.00 to $40.00 and gave the stock an “outperform” rating in a research note on Monday, May 11th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Artiva Biotherapeutics currently has an average rating of “Moderate Buy” and an average price target of $39.00.

Hedge Funds Weigh In On Artiva Biotherapeutics

A number of large investors have recently bought and sold shares of the business. ADAR1 Capital Management LLC purchased a new stake in Artiva Biotherapeutics during the second quarter worth $1,151,000. Blue Owl Capital Holdings LP purchased a new position in shares of Artiva Biotherapeutics in the 2nd quarter valued at $8,483,000. Nantahala Capital Management LLC purchased a new position in shares of Artiva Biotherapeutics in the 2nd quarter valued at $2,910,000. 5AM Venture Management LLC bought a new position in shares of Artiva Biotherapeutics in the 2nd quarter worth $22,827,049. Finally, Alyeska Investment Group L.P. raised its position in shares of Artiva Biotherapeutics by 173.6% in the 2nd quarter. Alyeska Investment Group L.P. now owns 273,615 shares of the company’s stock worth $2,654,000 after acquiring an additional 173,615 shares in the last quarter.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.